Adagrasib在KRYSTAL-1试验中对KRASG12C突变非小细胞肺癌未治疗中枢神经系统转移患者的颅内疗效
KRYSTAL-1试验Ib期队列纳入25例KRASG12C突变非小细胞肺癌伴未治疗中枢神经系统转移患者,口服Adagrasib 600 mg每日两次。19例可影像学评估颅内活动,颅内客观缓解率42%,疾病控制率90%,中位无进展生存期5.4个月,中位总生存期11.4个月。安全性与此前报告一致,3级治疗相关不良事件10例(40%)。
要点
- Adagrasib 600 mg口服每日两次在KRASG12C突变NSCLC未治疗CNS转移患者中颅内客观缓解率42%,疾病控制率90%。
- 中位随访13.7个月,中位颅内无进展生存期5.4个月,中位总生存期11.4个月。
- 3级治疗相关不良事件10例(40%),4级1例(4%),无5级;常见CNS相关不良事件为味觉障碍(24%)和头晕(20%)。
核心结论
- Adagrasib是首个在KRASG12C突变NSCLC伴未治疗CNS转移患者中前瞻性证实颅内活性的KRASG12C抑制剂,支持在该人群中进一步研究。
研究设计与样本
- KRYSTAL-1试验(NCT03785249)Ib期队列,纳入25例KRASG12C突变NSCLC伴未治疗CNS转移患者,Adagrasib 600 mg口服每日两次,中位随访13.7个月,19例可影像学评估颅内活动。
主要发现
- 颅内客观缓解率42%,疾病控制率90%,中位无进展生存期5.4个月,中位总生存期11.4个月。
- 3级治疗相关不良事件10例(40%),4级1例(4%),无5级治疗相关不良事件。
- 最常见CNS相关治疗相关不良事件为味觉障碍(24%)和头晕(20%)。
- 安全性与此前Adagrasib报告一致。
局限性
- 19例可影像学评估颅内活动,样本量有限。
- 原文结论指出支持在该人群中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Patients with Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated non-small-cell lung cancer (NSCLC) and untreated CNS metastases have a worse prognosis than similar patients without KRAS mutations. Adagrasib has previously demonstrated CNS penetration preclinically and cerebral spinal fluid penetration clinically. We evaluated adagrasib in patients with KRASG12C-mutated NSCLC and untreated CNS metastases from the KRYSTAL-1 trial (ClinicalTrials.gov identifier: NCT03785249; phase Ib cohort), in which adagrasib 600 mg was administered orally, twice daily. Study outcomes included the safety and clinical activity (intracranial [IC] and systemic) by blinded independent central review. Twenty-five patients with KRASG12C-mutated NSCLC and untreated CNS metastases were enrolled and evaluated (median follow-up, 13.7 months); 19 patients were radiographically evaluable for IC activity. Safety was consistent with previous reports of adagrasib, with grade 3 treatment-related adverse events (TRAEs) in 10 patients (40%) and one grade 4 (4%) and no grade 5 TRAEs. The most common CNS-specific TRAEs included dysgeusia (24%) and dizziness (20%). Adagrasib demonstrated an IC objective response rate of 42%, disease control rate of 90%, progression-free survival of 5.4 months, and median overall survival of 11.4 months. Adagrasib is the first KRASG12C inhibitor to prospectively demonstrate IC activity in patients with KRASG12C-mutated NSCLC and untreated CNS metastases, supporting further investigation in this population.
引用
- Negrao MV, Spira AI, Heist RS, et al. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. J Clin Oncol. 2023. PMID: 37327468. doi:10.1200/JCO.23.00046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。